Clinical Trial NRG BR003
- A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
- Principal Investigator
- William Gradishar
- Status: Accepting New Patients
- Study Type: Therapeutic, Treatment
- Protocol No:.NRG BR003
- The purpose of this study is to compare the good and bad effects of the chemotherapy drug, carboplatin, given with the usual chemotherapy drugs after surgery, compared to the usual chemotherapy drugs given without carboplatin.
- This study will allow the researchers to know whether giving carboplatin with the usual chemotherapy is better, the same, or worse than giving the usual chemotherapy. If giving carboplatin with the usual chemotherapy drugs is better, there should be a higher chance that your breast cancer will not return. Carboplatin is FDA-approved for the treatment of cancer and is used for the treatment of breast cancer that has spread, but it has not yet been proven useful in earlier stages of breast cancer.
Some of the eligibility criteria include:
- Participants must be 18 years of age or older.
- Participants must have breast cancer that is HER2-negative and is not sensitive to hormone treatment.
- Participant must have already been treated with surgery.
- Description of Treatment
- This study has two study groups. Group 1 will get the usual chemotherapy drugs used for this type of cancer: doxorubicin and cyclophosphamide, followed by paclitaxel.Group 2 will get the usual chemotherapy drugs used for this type of cancer: doxorubicin and cyclophosphamide, followed by paclitaxel plus the chemotherapy drug called carboplatin.
- Clinical Trials Recruitment Nurse
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
Other Clinical Trials by William Gradishar
- A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
- Phase II Study of Pembrolizumab and Capecitabine for Advanced Triple Negative and Hormone-Refractory Breast Cancer
last updated: 19-Oct-17 07:34 AM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.